Lupeng Pharmaceutical Ventures into Hong Kong Stock Exchange: Can Antimicrobial Resistance Inhibitors Shape an 18A New Tale?

Lupeng Pharmaceutical, a Guangzhou-based company, is making its second attempt at a mainboard IPO on the Hong Kong Stock Exchange. The company’s key asset, LP-168, a “covalent + non-covalent” dual mechanism BTK inhibitor, has entered the NDA stage in China, becoming the first of its kind in the country.…

Source